keyword
MENU ▼
Read by QxMD icon Read
search

Ulcer colitis

keyword
https://www.readbyqxmd.com/read/28092307/the-prosit-bio-cohort-a-prospective-observational-study-of-patients-with-inflammatory-bowel-disease-treated-with-infliximab-biosimilar
#1
Gionata Fiorino, Natalia Manetti, Alessandro Armuzzi, Ambrogio Orlando, Angela Variola, Stefanos Bonovas, Fabrizio Bossa, Giovanni Maconi, Renata DʼIncà, Paolo Lionetti, Laura Cantoro, Walter Fries, Maria L Annunziata, Francesco Costa, Maria M Terpin, Livia Biancone, Claudio C Cortelezzi, Arnaldo Amato, Sandro Ardizzone, Silvio Danese, Luisa Guidi, Giulia Rizzuto, Arianna Massella, Angelo Andriulli, Alessandro Massari, Greta Lorenzon, Silvia Ghione, Anna Kohn, Agostino Ventra, Vito Annese
BACKGROUND: Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease. METHODS: A prospective, multicenter, cohort study using a structured database. RESULTS: Consecutive patients (313 Crohn's disease and 234 ulcerative colitis) were enrolled from 31 referral centers; 311 patients were naive to anti-tumor necrosis factor alpha, 139 had a previous exposure to biologics, and the remaining 97 were switched to CT-P13 after a mean of 18 ± 14 infusions of infliximab...
January 12, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28092306/tripeptide-k-d-pt-is-well-tolerated-in-mild-to-moderate-ulcerative-colitis-results-from-a-randomized-multicenter-study
#2
Torsten Kucharzik, Gunter Lemmnitz, Christoph Abels, Christian Maaser
BACKGROUND: K(D)PT showed marked anti-inflammatory properties in preclinical studies and exhibited very low toxicity in phase I and preclinical trials. In this study, efficacy and safety of oral K(D)PT were evaluated in patients with mild-to-moderate active ulcerative colitis. METHODS: A multicenter, randomized, double-blind, phase IIa trial was performed comparing add-on oral K(D)PT twice a day (20, 50, or 100 mg) with placebo in patients with mild-to-moderate active ulcerative colitis on baseline medication...
January 12, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28092305/prevalence-and-impact-of-inflammatory-bowel-disease-irritable-bowel-syndrome-on-patient-reported-outcomes-in-ccfa-partners
#3
Maisa I Abdalla, Robert S Sandler, Michael D Kappelman, Christopher F Martin, Wenli Chen, Kristen Anton, Millie D Long
BACKGROUND: Inflammatory bowel disease (IBD) patients with persistent symptoms despite no or minimal inflammation are frequently described as having an overlap of IBD and irritable bowel syndrome (IBD-IBS). Limited data are available on how IBS impacts the individual patient with IBD. In this study, we aimed to evaluate the prevalence of IBD-IBS and investigate its impact on patient-reported outcomes. METHOD: We performed a cross-sectional analysis within the CCFA Partners Study...
January 12, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28092152/issues-in-nutrition-dietary-considerations-in-select-chronic-conditions
#4
Margaret E Thompson, Mary Barth Noel
Chronic diseases that affect the gastrointestinal tract also tend to affect nutrition. The incidence of chronic liver disease is increasing. As the prevalence of obesity rises, so do the incidences of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Patients with chronic liver disease usually have some degree of malnutrition. In the absence of encephalopathy, patients with chronic liver disease should consume more protein than that in the average diet. There is some controversy about whether diet plays a role in the development of inflammatory bowel disease...
January 2017: FP Essentials
https://www.readbyqxmd.com/read/28091842/squamous-cell-dysplasia-in-the-proximal-rectum-of-three-patients-treated-for-ulcerative-colitis-on-immunomodulators
#5
James G Connolly, Stephen E Goldstone
BACKGROUND: Anal canal high-grade squamous intraepithelial lesion (HSIL) is the precursor to anal cancer. Immunocompromised patients are at increased risk and disease is usually within 3 cm from the anal verge. High-resolution anoscopy (HRA) with an 8-cm anoscope is used to identify and guide cautery treatment of HSIL. PURPOSE: We report three patients with a long-term history of ulcerative colitis (UC) treated with systemic immunomodulators who developed proximally located rectal HSIL...
January 13, 2017: International Journal of Colorectal Disease
https://www.readbyqxmd.com/read/28089625/azathioprine-for-refractory-ulcerative-proctitis-a-retrospective-multicenter-study
#6
Anne-Laure Mallet, Guillaume Bouguen, Guillaume Conroy, Xavier Roblin, Jean-Bernard Delobel, Jean-François Bretagne, Laurent Siproudhis, Laurent Peyrin-Biroulet
BACKGROUND: Efficacy of azathioprine (AZA) in refractory ulcerative proctitis (UP) is unknown. METHODS: All patients treated with AZA for refractory UP in three referral centers between 2002 and 2012 were included. "Treatment success" in the long-term was defined as the absence of colectomy during follow-up, no need for anti-TNF during follow-up, no ongoing systemic steroids use, no adverse event leading to AZA withdrawal, and clinically quiescent disease at last follow-up...
December 13, 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28088612/alterations-in-cytokine-gene-expression-profile-in-colon-mucosa-of-inflammatory-bowel-disease-patients-on-different-therapeutic-regimens
#7
Tsvetelina Velikova, Dobroslav Kyurkchiev, Zoya Spassova, Iliya Karakolev, Ekaterina Ivanova-Todorova, Iskra Altankova, Spaska Stanilova
Inflammatory bowel disease (IBD) is assumed to be caused by genetic and environmental factors that interact together in promoting intestinal immune dysregulation where cytokines have validated role. However, the underlying intimate mechanisms in the human IBD involving cytokines still needs to be supplemented especially in the clinical context. The aim of this study was to investigate the expression of some inflammatory and regulatory cytokines (IL-17A, IL-23, IL-6, TGFβ1, and IL-10) as well as of the transcription factor FoxP3 in mucosal samples of IBD and non-IBD patients...
January 12, 2017: Cytokine
https://www.readbyqxmd.com/read/28079625/older-age-and-health-related-quality-of-life-in-inflammatory-bowel-diseases
#8
Gabriella Velonias, Grace Conway, Elizabeth Andrews, John J Garber, Hamed Khalili, Vijay Yajnik, Ashwin N Ananthakrishnan
BACKGROUND: The burden of inflammatory bowel disease (IBD) in the older population is increasing. Older-onset disease is associated with reduced use of immunosuppressive medications. In addition, older patients may be more vulnerable to the effect of disease-related symptoms and consequently may experience worse health-related quality of life (HRQoL) compared with younger patients. METHODS: This prospective study included a cohort of patients with Crohn's disease and ulcerative colitis recruited from a single center...
January 6, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28079623/the-ileitis-of-ulcerative-colitis-why-is-it-not-crohn-s-disease
#9
Burton I Korelitz, Steven Shamah
No abstract text is available yet for this article.
January 10, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28079622/prevalence-and-determinants-of-job-stress-in-patients-with-inflammatory-bowel-disease
#10
Philipp Schreiner, Luc Biedermann, Jean-Benoit Rossel, Gerhard Rogler, Valérie Pittet, Roland von Känel
BACKGROUND: Psychosocial factors have been shown to predict a poor disease course in patients with inflammatory bowel disease (IBD), but whether this applies to job stress is currently unknown. We assessed the prevalence of job stress and its correlates in a large cohort of patients with IBD. METHODS: We included all adult, professionally active patients enrolled between 2006 and 2015 in the Swiss IBD Cohort. Job stress was measured through the self-report effort-reward imbalance ratio and overcommitment (OC) to work questionnaires...
January 10, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28079620/clostridium-difficile-infection-and-risk-of-colectomy-in-patients-with-inflammatory-bowel-disease-a-bias-adjusted-meta-analysis
#11
Yingxi Chen, Luis Furuya-Kanamori, Suhail A Doi, Ashwin N Ananthakrishnan, Martyn Kirk
BACKGROUND: Clostridium difficile infection (CDI) is a common complication of inflammatory bowel diseases (IBDs) and is associated with worse outcome. Variable rates of colectomy have been reported among IBD complicated by CDI. We conducted a systematic review and meta-analysis of studies to assess the association between CDI and colectomy among patients with IBD. METHODS: The literature was systematically searched using PubMed from inception through April 2016...
January 10, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28079248/inhibition-of-matrix-metalloproteinase-9-by-a-barbiturate-nitrate-hybrid-ameliorates-dextran-sulphate-sodium-induced-colitis-effect-on-inflammation-related-genes
#12
Shane O'Sullivan, Jun Wang, Maria T Pigott, Neil Docherty, Noreen Boyle, Samuel Kana Lis, John F Gilmer, Carlos Medina
BACKGROUND AND PURPOSE: Matrix metalloproteinase-9 is upregulated in Ulcerative Colitis and implicated in the pathology of the disease. In this study, we have examined the effects of a barbiturate-based MMP inhibitor incorporating a nitric oxide donor/mimetic group (dinitrate-barbiturate) in the intestinal injury induced by dextran sulphate sodium (DSS). EXPERIMENTAL APPROACH: In-vivo experiments were carried out using male Wistar rats given DSS 5% ad libitum in drinking water...
January 12, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28078747/granulocyte-monocyte-apheresis-as-an-adjuvant-therapy-to-anti-tumor-necrosis-factor-drugs-for-ulcerative-colitis
#13
Iago Rodríguez-Lago, Laura Gómez-Irwin, Encarnación Fernández, Rebeca Higuera, José Luis Cabriada
Biologic anti-tumor necrosis factor (TNF) drugs have demonstrated their efficacy for the treatment of ulcerative colitis. Nevertheless, some patients will not respond to this therapy or will develop loss of response. Leukapheresis is the main non-pharmacological therapy for some immune-mediated diseases. The aim of our study was to describe our experience with this therapy in ulcerative colitis patients after loss of response to anti-TNF treatment. Leukapheresis was indicated in four patients with left-sided or extensive colitis because of partial response to biological therapy or secondary loss of response to it...
January 11, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28078646/mucosal-healing-in-ulcerative-colitis-a-comprehensive-review
#14
REVIEW
Pedro Boal Carvalho, José Cotter
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by periods of remission and periods of relapse. Patients often present with symptoms such as rectal bleeding, diarrhea and weight loss, and may require hospitalization and even colectomy. Long-term complications of UC include decreased quality of life and productivity and an increased risk of colorectal cancer. Mucosal healing (MH) has gained progressive importance in the management of UC patients. In this article, we review the endoscopic findings that define both mucosal injury and MH, and the strengths and limitations of the scoring systems currently available in clinical practice...
January 11, 2017: Drugs
https://www.readbyqxmd.com/read/28077249/altered-mucosal-expression-of-micrornas-in-pediatric-patients-with-inflammatory-bowel-disease
#15
Nóra Judit Béres, Zoltán Kiss, Zsófia Sztupinszki, Gábor Lendvai, András Arató, Erna Sziksz, Ádám Vannay, Attila J Szabó, Katalin Eszter Müller, Áron Cseh, Kriszta Boros, Gábor Veres
INTRODUCTION: MicroRNAs (miRs) came recently into focus as promising novel research targets offering new insights into the pathogenesis of inflammatory bowel diseases (IBD). AIMS: The aim of our study was to identify a pediatric IBD (pIBD) characteristic miR profile serving as potential Crohn's disease (CD) and ulcerative colitis (UC) specific diagnostic pattern and to further analyze the related target genes. METHODS: Small RNA sequencing was performed on inflamed and intact colonic biopsies of CD, and control patients...
December 27, 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28076386/neutrophil-to-lymphocyte-ratio-for-predicting-loss-of-response-to-infliximab-in-ulcerative-colitis
#16
Yu Nishida, Shuhei Hosomi, Hirokazu Yamagami, Tomomi Yukawa, Koji Otani, Yasuaki Nagami, Fumio Tanaka, Koichi Taira, Noriko Kamata, Tetsuya Tanigawa, Masatsugu Shiba, Kenji Watanabe, Toshio Watanabe, Kazunari Tominaga, Yasuhiro Fujiwara
OBJECTIVES: Neutrophil-to-lymphocyte ratio (NLR) has been used to determine the outcome in malignancies and coronary heart disease. Some reports considered the value of NLR as a predictor of response to infliximab in patients with Crohn's disease or rheumatoid arthritis; however, no similar studies have been reported for ulcerative colitis (UC). This study aimed to evaluate the clinical significance of the baseline NLR in patients with UC treated by infliximab. MATERIALS AND METHODS: Patients with moderate-to-severe active UC who received the first infliximab infusion in our hospital between 2010 and 2015, who showed clinical response during the induction period, were retrospectively evaluated for long-term outcomes and risk factors for loss of response (LOR) during infliximab maintenance therapy...
2017: PloS One
https://www.readbyqxmd.com/read/28074618/review-article-dose-optimisation-of-infliximab-for-acute-severe-ulcerative-colitis
#17
REVIEW
P Hindryckx, G Novak, N Vande Casteele, D Laukens, C Parker, L M Shackelton, N Narula, R Khanna, P Dulai, B G Levesque, W J Sandborn, G D'Haens, B G Feagan, V Jairath
BACKGROUND: Although optimal medical management of acute severe ulcerative colitis (UC) is ill-defined, infliximab has become a standard of care. Accumulating evidence suggests an increased rate of infliximab clearance in patients with acute severe UC and a reduced colectomy rate with an intensified infliximab induction regimen. AIM: To assess the strength of the current evidence for the relationship between infliximab pharmacokinetics, dosing strategies and disease behaviour in patients with acute severe UC...
January 11, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28071183/5-aminosalicylic-acid-inhibits-inflammatory-responses-by-suppressing-jnk-and-p38-activity-in-murine-macrophages
#18
Tingli Qu, Erbing Wang, Baofen Jin, Weiping Li, Ruiling Liu, Zheng-Bao Zhao
CONTEXT: 5-Aminosalicylic acid (5-ASA), as an anti-inflammatory drug, has been extensively used for the treatment of mild to moderate active ulcerative colitis (UC), but the possible mechanisms of action remain unclear. OBJECTIVE: To investigate the effects of 5-ASA on the production of inflammatory mediators by murine macrophages stimulated with lipopolysaccharide (LPS), and determine the underlying pharmacological mechanism of action. MATERIALS AND METHODS: The levels of nitric oxide (NO) and interleukin-6 (IL-6) were measured by Varioskan Flash and IL-6 Enzyme-Linked Immunosorbent Assay sets...
February 2017: Immunopharmacology and Immunotoxicology
https://www.readbyqxmd.com/read/28070861/efficacy-and-safety-of-vedolizumab-in-ulcerative-colitis-and-crohn-s-disease-patients-stratified-by-age
#19
Vijay Yajnik, Nabeel Khan, Marla Dubinsky, Jeffrey Axler, Alexandra James, Brihad Abhyankar, Karen Lasch
INTRODUCTION: The efficacy and safety of vedolizumab, a gut-selective α4β7 integrin antibody, were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18-80 years. We investigated the efficacy and safety of vedolizumab in patients stratified by age from the GEMINI trials. METHODS: Safety and efficacy, including clinical response, clinical remission, and corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients aged <35, 35 to <55, and ≥55 years...
January 9, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28069913/anti-tnf%C3%AE-antibody-induced-psoriasiform-skin-lesions-in-patients-with-inflammatory-bowel-disease-an-irish-cohort-study
#20
S Kirthi, A-M Tobin, M Hussey, F Scaldaferri, D McNamara
AIM: To determine the prevalence of psoriasis in an IBD cohort with reference to clinical characteristics and anti-TNFα use. METHODS: Patients with psoriasis and IBD were retrospectively identified from the IBD database at Tallaght Hospital from 2000 to 2015. Pertinent clinical data were obtained from patients notes including anti-TNFα exposure. Prevalence rates of genuine and reactive psoriasis were calculated and compared using a students T-test. A p value of < 0...
January 9, 2017: QJM: Monthly Journal of the Association of Physicians
keyword
keyword
7016
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"